Evidence to experience: JAKi in Rheumatology

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Evidence to experience: JAKi in Rheumatology
Janus kinase inhibitors (JAKi) have emerged as a significant advancement in the treatment of various rheumatologic conditions, notably rheumatoid arthritis (RA). Clinical trials have consistently demonstrated their efficacy in reducing symptoms and halting disease progression. JAK inhibitors work by targeting the JAK-STAT signaling pathway, crucial in the pathogenesis of inflammatory and autoimmune diseases. Studies show that JAKi can be as effective as traditional biologics, with the added benefit of oral administration, improving patient compliance and convenience.
Real-world experience with JAK inhibitors has reinforced clinical trial findings, highlighting their effectiveness in diverse patient populations, including those with inadequate responses to conventional therapies. Long-term safety data is accumulating, providing a clearer picture of potential risks such as infections and thrombosis, which necessitates vigilant monitoring. Nevertheless, the benefits of JAK inhibitors in reducing disease activity and improving quality of life for patients with RA and other rheumatic diseases are substantial.
Therefore, get an overall knowledge of evidence to experience: JAKi in rheumatology
 

See More Webinars @ Hidoc Webinars